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Study Type: This study was a retrospective, matched cohort
Sample Size: 63,008 individuals
Length of Study: 8 years were included in the study (1996-2004)
Objective: To examine the relation between duration of exposure to proton pump 
inhibitors and osteoporosis-related fractures. 
Conclusion: The study found that the use of PPIs increases the risk of hip fracture after 5 
or more years of continuous exposure, and the risk of any osteoporotic fracture was 
increased after the 7 years of continuous exposure to PPIs.
Critique: Strengths: Researchers included patients from a very large time period (1996-
2004) so they were able to pinpoint which year of continuous PPI use they started seeing 
an association with increased fractures. Another strength of the study was that they used 3 
matched controls for every case they included in the study. Limitations: They were not 
able to obtain information about the use of over-the-counter medications such as calcium 
and vitamin D supplements. They were unable to determine whether increased fracture risk 
from PPIs were related to reduced bone density or increased risk for falls.
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Among individuals 50 years and older, does the long-term use of proton pump 
inhibitor therapy increase the incidence of fractures as compared to similar 
populations who do not use long-term PPIs? 
Reconstructed side
INTRODUCTION
Since their introduction in the late 1980s, proton pump inhibitors (PPIs) have become 
one of the most widely used class of drugs, and one of the most commonly 
prescribed medications in clinical practice.  PPIs treat a variety of acid related 
disorders including: peptic ulcer disease (PUD), H. pylori, NSAID-related ulcers, 
Zollinger-Ellison Syndrome, and gastroesophageal reflux disease (GERD). 
All PPIs share a common structure, and accumulate selectively in the highly acidic 
space within the parietal cell.  The drugs interact with the surface of the H-K-ATPase 
proton pump, inhibiting this enzyme, and resulting in 
specific and long-lasting decrease in gastric acid 
secretion.  PPIs are one of the most potent gastric
acid secretion inhibitors on the market today. 
Long-term effects include hypochlorhydria, 
hypergastrinemia, and gastric atrophy.  
Hypochlorhydria is believed to be associated 
with an increased risk of infection and 
malabsorption of vitamins such as vitamin B12. It is believed that gastric acid 
secretion might help facilitate the absorption of calcium, so the use of acid 
suppressants like proton pump inhibitors have been linked to decreased calcium 
absorption and decreased bone density. Another mechanism that has been looked at 
was long term acid suppression leading to both primary and secondary 
hyperparathyroidism, which in turn leads to increased bone resorption and decreased 
bone strength.
Due to the high use of long-term PPI therapy in elderly women, and their overall risk 
of falling as a general population, the association between increased fall risk and PPI 
exposure is an extremely important relationship to investigate. All of the research 
articles compared in this study found a significantly increased association between 
long-term PPI use with falls and fractures. Even minor increases in fractures in this 
population may have permanent effects on the absolute risk of events and their 
associated cost to an individual and society. Physicians should be aware of this 
potential association when considering prescribing long-term PPIs to their patients, 
and only use them in the smallest doses possible, and only when they are extremely 
necessary and proven to be efficacious. Further study should be done to examine the 
possible mechanisms for this association including the effect of acid inhibition on 
calcium absorption and bone mineral density.
1. Wolfe M. Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid 




related%20disorders&selectedTitle=1~150#topicContent. Published October 2017.
2.  Lewis JR, Barre D, Zhu K, et al. Long-term proton pump inhibitor therapy and falls and 
fractures in elderly women: a prospective cohort study. J Bone Miner Res Off J Am Soc Bone 
Miner Res. 2014;29(11):2489-2497. doi:10.1002/jbmr.2279.
3.  Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors 
and risk of osteoporosis-related fractures. CMAJ Can Med Assoc J. 2008;179(4):319-326. 
doi:10.1503/cmaj.071330.
4.  Bo-linn G, Davis G, Buddrus D, Morawski S, Santa Ana C, Fordtran J. An evaluation of the 
Importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 
1984;73(3):640-647.
5. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term Proton Pump Inhibitor Therapy and Risk 
of Hip Fracture. JAMA. 2006;296(24):2947-2953. doi:10.1001/jama.296.24.2947.
6. Murphy A, Gaillard F. Femoral Neck Fracture. Radiopaedia. 
https://radiopaedia.org/articles/femoral-neck-fracture. Published 2017.
7.  Moher D,  Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): 
e1000097. doi:10.1371/journal.pmed1000097
ACKNOWLEDGEMENTS
We would like to thank Dr. Erika Kancler, Carolyn Schubert, and the James Madison 
University’s Graduate Writing & Communication Center for all the time they all gave 
us to help us complete this project.
Study 1: Use of proton pump inhibitors and risk of osteoporosis related 
fractures. Targownik et al.
Study 2: Long-term proton pump inhibitory therapy and falls and 
fracture in elderly women: A prospective cohort study. Lewis et al.
Study Type: Prospective cohort study, replicating a longitudinal population-based 
prospective cohort study
Sample Size: Study #1: 1,025 individuals; Replication study: 686 individuals
Length of Study: Study #1: 5 years; Replication study: 9 months
Objective: To examine the association in elderly postmenopausal women between PPI use 
greater than or equal to one year (“long-term use”) and fracture risk factors, including 
bone structure, falls, and balance-related functioning.
Conclusion: Study #1: There was an association between long-term PPI use and increased 
fall risk and hospitalizations related to fractures; Replication study: There was an 
association between long-term PPI use and increased risk of falling (self-reported).  No 
associations were found between long-term PPI use and bone structure, but users with 
long-term PPI exposure were more likely to have low vitamin B12 levels than those who 
did not have the long-term PPI exposure.
Critique: Strengths: Use of comprehensive prospective information collected regularly 
over a 5-year period.  Important information was used, including duration, dose, 
frequency, and type of PPI exposure.   The use of hospital records eliminated patient recall 
bias or error in self-reporting. Limitations:  Observational studies only identify association 
(not causation).  Findings of the study can only be applied to similar populations of 
postmenopausal women with mean age of 80. 
Study Type: Nested case-control study
Sample Size: 148,942 individuals
Length of Study: 16 years were included in the study (1987-2003)
Objective: To determine the association between PPI therapy and risk of hip fracture. 
Conclusion: Long term PPI use >1 year is associated with a statically significant increased 
risk of hip fractures. The longer the treatment with PPIs, the greater the association with 
increased fracture risk. They also found that the fracture risk increased with higher doses 
of PPI therapy. The study also found that the interaction between PPI therapy and sex was 
statistically significant, with men being at a higher risk for fractures.
Critique: Strengths: A strength of this study was that it used a very large population size. 
Another strength of this study was that it used up to 10 very well-matched controls for 
each case. This study also used patients for a very large time period (1987-2003) which 
helped determine long term data. Limitations: One weakness of this study was that there 
was no way for them to determine if the patients had continued to take their prescriptions 
for the full time it was prescribed or if they had taken PPIs prior to being enrolled. They 
were also unable to determine if participants were taking over the counter calcium 
supplements during the study period.
Study 3:Long-term Proton Pump Inhibitor Therapy and Risk of Hip 
Fracture. Yang et al.
METHODS
Image 1. Left femoral neck fracture 6
